Aemetis (NASDAQ:AMTX) Director Francis P. Barton Sells 26,452 Shares

Key Points

• Francis P. Barton, a director of Aemetis, Inc, sold 26,452 shares of stock at an average price of $2.53, reducing his ownership by 11.26%.
• Aemetis reported a quarterly EPS of ($0.41), missing estimates, with revenue of $52.24 million compared to expectations of $78.68 million.
• Research firms have upgraded Aemetis' target price, with Ascendiant Capital Markets increasing it from $19.00 to $20.00 and UBS from $2.20 to $3.00, both giving the stock a "buy" rating.

Aemetis, Inc (NASDAQ:AMTX - Get Free Report) Director Francis P. Barton sold 26,452 shares of the business's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $2.53, for a total value of $66,923.56. Following the completion of the sale, the director owned 208,518 shares in the company, valued at approximately $527,550.54. This trade represents a 11.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Aemetis Trading Down 3.0%

Shares of Aemetis stock traded down $0.0750 during trading on Tuesday, reaching $2.3850. The stock had a trading volume of 157,339 shares, compared to its average volume of 953,741. The company has a market capitalization of $150.83 million, a price-to-earnings ratio of -1.47 and a beta of 1.49. The stock has a fifty day moving average price of $2.67 and a two-hundred day moving average price of $2.05. Aemetis, Inc has a 52 week low of $1.22 and a 52 week high of $4.73.

Aemetis (NASDAQ:AMTX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The specialty chemicals company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The firm had revenue of $52.24 million during the quarter, compared to the consensus estimate of $78.68 million. On average, equities analysts forecast that Aemetis, Inc will post -2.07 EPS for the current fiscal year.

Analysts Set New Price Targets

AMTX has been the topic of a number of research reports. Ascendiant Capital Markets boosted their price target on Aemetis from $19.00 to $20.00 and gave the company a "buy" rating in a report on Friday, June 6th. UBS Group boosted their price target on Aemetis from $2.20 to $3.00 and gave the company a "buy" rating in a report on Monday, June 30th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $17.00.

Institutional Trading of Aemetis

Several institutional investors and hedge funds have recently bought and sold shares of AMTX. Catalyst Funds Management Pty Ltd bought a new stake in Aemetis during the second quarter worth about $25,000. ProShare Advisors LLC bought a new stake in Aemetis during the fourth quarter worth about $27,000. Voya Investment Management LLC acquired a new position in Aemetis during the fourth quarter worth approximately $28,000. Tower Research Capital LLC TRC increased its position in Aemetis by 128.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,407 shares of the specialty chemicals company's stock worth $28,000 after buying an additional 5,859 shares during the last quarter. Finally, R Squared Ltd acquired a new position in Aemetis during the second quarter worth approximately $30,000. Institutional investors own 27.02% of the company's stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.